Iovance Biotherapeutics, Inc.
IOVA
$3.06
-$0.01-0.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -372.18M | -410.00M | -440.22M | -449.64M | -444.04M |
| Total Depreciation and Amortization | 43.61M | 41.63M | 40.36M | 37.34M | 33.13M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 98.15M | 77.40M | 64.58M | 54.26M | 55.61M |
| Change in Net Operating Assets | -122.56M | -72.69M | -53.48M | -26.24M | -6.52M |
| Cash from Operations | -352.98M | -363.65M | -388.76M | -384.28M | -361.82M |
| Capital Expenditure | -11.07M | -10.43M | -11.72M | -20.80M | -22.29M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -52.57M | -52.32M | -55.70M | -265.21M | -212.63M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -32.77M | -130.18M | -155.73M | -134.14M | 79.68M |
| Cash from Investing | -96.41M | -192.93M | -223.15M | -420.14M | -155.24M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 403.52M | 401.48M | 556.43M | 403.93M | 465.75M |
| Repurchase of Common Stock | -12.86M | -12.16M | -6.27M | -5.57M | -2.80M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 390.66M | 389.32M | 550.16M | 398.36M | 462.96M |
| Foreign Exchange rate Adjustments | -541.00K | 3.66M | 412.00K | -3.23M | -2.74M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -59.27M | -163.61M | -61.33M | -409.30M | -56.84M |